These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24840523)

  • 1. Optimal duration of systemic treatment in metastatic colorectal cancer.
    Simkens LH; Koopman M; Punt CJ
    Curr Opin Oncol; 2014 Jul; 26(4):448-53. PubMed ID: 24840523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatment: maintenance compared with holiday.
    Punt CJ; Simkens LH; Koopman M
    Am Soc Clin Oncol Educ Book; 2015; ():85-90. PubMed ID: 25993146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of maintenance therapy and complete discontinuation for therapeutic management of non-resectable metastatic colorectal cancer].
    Senellart H; Hiret S; Guerin-Meyer V; Bennouna J
    Bull Cancer; 2014 Jun; 101(6):619-25. PubMed ID: 24977450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy for colorectal cancer: which regimen and which patients?
    Mikhail S; Bekaii-Saab T
    Drugs; 2015 Nov; 75(16):1833-42. PubMed ID: 26377935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
    Cartwright TH
    Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.
    O'Neil BH; Goldberg RM
    Oncologist; 2008 Oct; 13(10):1074-83. PubMed ID: 18922828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Giantonio BJ
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenesis agents in colorectal cancer.
    Hubbard J; Grothey A
    Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer.
    Jain VK; Hawkes EA; Cunningham D
    Clin Colorectal Cancer; 2011 Dec; 10(4):245-57. PubMed ID: 21729675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
    Aprile G; Giuliani F; Lutrino SE; Fontanella C; Bonotto M; Rihawi K; Fasola G
    Clin Colorectal Cancer; 2016 Mar; 15(1):7-15. PubMed ID: 26421728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
    Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
    Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
    Sidhu R; Rong A; Dahlberg S
    Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.